Condition: Neurological Autoimmune Diseases · Sponsor: Grit Biotechnology
This study is an open-label, prospective, exploratory clinical trial that includes a dose escalation phase and a dose expansion phase, aimed at evaluating the safety, cell dynamics, and preliminary efficacy of GT719 cells in adult participants with recurrent/refractory antibody-mediated neurological immune diseases.
This description comes directly from the study's public registry record.
Daishi Tian · +8613607178809 · tiands@tjh.tjmu.edu.cn
Wei Wang · +86-27-83662640 · wwang@tjh.tjmu.edu.cn
Always discuss trial participation with your own doctor first.
| Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07021209